1. Home
  2. RLMD vs CMLS Comparison

RLMD vs CMLS Comparison

Compare RLMD & CMLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RLMD
  • CMLS
  • Stock Information
  • Founded
  • RLMD 2004
  • CMLS 2002
  • Country
  • RLMD United States
  • CMLS United States
  • Employees
  • RLMD N/A
  • CMLS N/A
  • Industry
  • RLMD Biotechnology: Pharmaceutical Preparations
  • CMLS Broadcasting
  • Sector
  • RLMD Health Care
  • CMLS Consumer Discretionary
  • Exchange
  • RLMD Nasdaq
  • CMLS Nasdaq
  • Market Cap
  • RLMD 11.5M
  • CMLS 12.4M
  • IPO Year
  • RLMD N/A
  • CMLS 1998
  • Fundamental
  • Price
  • RLMD $0.38
  • CMLS $0.82
  • Analyst Decision
  • RLMD Hold
  • CMLS Hold
  • Analyst Count
  • RLMD 4
  • CMLS 2
  • Target Price
  • RLMD $4.25
  • CMLS N/A
  • AVG Volume (30 Days)
  • RLMD 881.7K
  • CMLS 65.0K
  • Earning Date
  • RLMD 03-18-2025
  • CMLS 02-25-2025
  • Dividend Yield
  • RLMD N/A
  • CMLS N/A
  • EPS Growth
  • RLMD N/A
  • CMLS N/A
  • EPS
  • RLMD N/A
  • CMLS N/A
  • Revenue
  • RLMD N/A
  • CMLS $829,801,000.00
  • Revenue This Year
  • RLMD N/A
  • CMLS N/A
  • Revenue Next Year
  • RLMD N/A
  • CMLS N/A
  • P/E Ratio
  • RLMD N/A
  • CMLS N/A
  • Revenue Growth
  • RLMD N/A
  • CMLS N/A
  • 52 Week Low
  • RLMD $0.34
  • CMLS $0.63
  • 52 Week High
  • RLMD $7.22
  • CMLS $5.18
  • Technical
  • Relative Strength Index (RSI)
  • RLMD 27.23
  • CMLS 48.73
  • Support Level
  • RLMD $0.36
  • CMLS $0.75
  • Resistance Level
  • RLMD $0.49
  • CMLS $0.90
  • Average True Range (ATR)
  • RLMD 0.04
  • CMLS 0.07
  • MACD
  • RLMD 0.07
  • CMLS 0.00
  • Stochastic Oscillator
  • RLMD 12.64
  • CMLS 45.61

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

About CMLS Cumulus Media Inc.

Cumulus Media Inc is an audio-first media company delivering content to over a quarter billion people every month wherever and whenever required. It is a radio broadcasting company combining high-quality local programming with iconic, nationally syndicated media, sports, and entertainment brands to deliver premium content choices to its customers and radio stations affiliated with Westwood One network and numerous digital channels. The company's revenue is derived mainly from the sale of local, regional, and national advertising which is broadcast on its radio stations.

Share on Social Networks: